Skip to main content
. 2022 Jan 26;8:755806. doi: 10.3389/fcvm.2021.755806

Figure 4.

Figure 4

Hazard ratios for the primary endpoint according to the subgroups. ACS, acute coronary syndrome; NSTE-ACS, non ST-segment elevation acute coronary syndrome; STEMI, ST-segment elevation myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker.